Data Editor, Pharma
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From John Hodgson
The market slump at the beginning of February affected virtually all of the stocks of the top 50 pharmaceutical companies. But unpredicted clinical successes or surprisingly good financials still kept a few companies above water.
Venture capital investment in life sciences companies continues to rise. In 2017, biopharma and medtech start-ups raised $19.7 billion worldwide. European businesses retained a robust share of that global take and investors expect that trend to continue.
Most of the biggest pharmaceutical companies that pay taxes in Europe or North America have told the world how they got on in 2017. So what, other than the corrective value of financial performance minutiae, did we learn?
Big pharma stocks lost value overall in the fourth quarter of 2017 despite good performances from Asian companies and Kåre Schultz taking over at Teva.
As the reality of annual results arrive, Scrip predicts how the top of the pharma league table is likely to change.